# US 2020/0002346 A1 · Pyrazolochlorophenyl compounds, compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002346 A1
- Document ID: US20200002346A1
- Status: Published application
- Kind: A1
- Application number: 16/561,447
- Filed: 2019-09-05
- Published: 2020-01-02
- Earliest claimed: 2017-03-14
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Mark ZAK; F. Anthony ROMERO; Po-wai YUEN; Emily J. HANAN
- Web page: https://patentgrep.com/patent/US20200002346A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 11/06: Antiasthmatics
- C07D 471/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 498/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.

## Claims

### Claim 1

A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C2-C6alkenyl, C2-C6alkynyl, —(C0-C3alkyl)CN, —(C0-C3alkyl)ORa, —(C0-C3alkyl)Ra, —(C0-C3alkyl)SRa, —(C0-C3alkyl)NRaRb, —(C0-C3alkyl)OCF3, —(C0-C3alkyl)CF3, —(C0-C3alkyl)NO2, —(C0-C3alkyl)C(O)Ra, —(C0-C3alkyl)C(O)ORa, —(C0-C3alkyl)C(O)NRaRb, —(C0-C3alkyl)NRaC(O)Rb, —(C0-C3alkyl)S(O)1-2Ra, —(C0-C3alkyl)NRaS(O)1-2Rb, —(C0-C3alkyl)S(O) 12NRaRb, —(C0-C3alkyl)(5-6-membered heteroaryl) or —(C0-C3alkyl)phenyl, wherein R1 is optionally substituted by halogen, C1-C3alkyl, oxo, —CF3, —(C0-C3alkyl)ORc or —(C0-C3alkyl)NRcRd;
each Ra is independently selected from the group consisting of hydrogen, C1-C6alkyl, C3-C6 cycloalkyl, 3-10 membered heterocyclyl, 5-6 membered heteroaryl, —C(O)Rc, —C(O)ORc, —C(O)NRcRd, —NRcC(O)Rd, —S(O)1-2Rc, —NRcS(O)1-2Rd and —S(O)1-2NRcRd, wherein any C3-C6 cycloalkyl, 3-10 membered heterocyclyl, and 5-6 membered heteroaryl of Ra is optionally substituted with Re;
each Rb is independently selected from the group consisting of hydrogen and C1-C3alkyl, wherein said alkyl is optionally substituted halogen or oxo;
each Rc and Rd is independently selected from the group consisting of hydrogen, 3-6 membered heterocyclyl, C3-C6 cycloalkyl, and C1-C3alkyl, wherein any 3-6 membered heterocyclyl, C3-C6 cycloalkyl, and C1-C3alkyl of Rc and Rd is optionally substituted by halogen or oxo; or Rc and Rd are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl, optionally substituted by halogen, oxo, —CF3 or C1-C3alkyl;
each Re is independently selected from the group consisting of oxo, ORf, NRfRg, halogen, 3-10 membered heterocyclyl, C3-C6 cycloalkyl, and C1-C6alkyl, wherein any C3-C6 cycloalkyl and C1-C6alkyl of Re is optionally substituted by ORf, NRfRg, halogen, 3-10 membered heterocyclyl, oxo, or cyano, and wherein any 3-10 membered heterocyclyl of Re is optionally substituted by halogen, oxo, cyano, —CF3, NRhRk, 3-6 membered heterocyclyl, or C1-C3alkyl that is optionally substituted by halogen, oxo, ORf, or NRhRk;
each Rf and Rg is independently selected from the group consisting of hydrogen, C1-C6alkyl, 3-6 membered heterocyclyl, and C3-C6 cycloalkyl, wherein any C1-C6alkyl, 3-6 membered heterocyclyl, and C3-C6 cycloalkyl of Rf and Rg is optionally substituted by Rm;
each Rh and Rk is independently selected from the group consisting of hydrogen and C1-C6alkyl that is optionally substituted by halogen, cyano, 3-6 membered heterocyclyl, or oxo; or Rh and Rk are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl that is optionally substituted by halogen, cyano, oxo, —CF3 or C1-C3alkyl that is optionally substituted by halogen or oxo;
each Rm is independently selected from the group consisting of halogen, cyano, oxo, C3-C6cycloalkyl, hydroxy, and NRhRk, wherein any C3-C6cycloalkyl of Rm is optionally substituted with halogen, oxo, cyano, or C1-C3alkyl;
R2 is phenyl, 5-6 membered heteroaryl, C3-C6 cycloalkyl or 3-10 membered heterocyclyl, wherein R2 is optionally substituted by 1-5 Rn;
each Rn is independently selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, oxo, halogen, —(C0-C3 alkyl)CN, —(C0-C3 alkyl)ORo, —(C0-C3 alkyl)SRo, —(C0-C3 alkyl)NRoRp, —(C0-C3 alkyl)OCF3, —(C0-C3 alkyl)CF3, —(C0-C3 alkyl)NO2, —(C0-C3 alkyl)C(O)Ro, —(C0-C3 alkyl)C(O)ORo, —(C0-C3 alkyl)C(O)NRoRp, —(C0-C3 alkyl)NRoC(O)Rp, —(C0-C3 alkyl)S(O)1-2Ro, —(C0-C3 alkyl)NRoS(O)1-2Rp, —(C0-C3 alkyl)S(O)1-2NRoRp, —(C0-C3 alkyl)(C3-C6 cycloalkyl), —(C0-C3 alkyl)(3-6-membered heterocyclyl), —(C0-C3 alkyl)C(O)(3-6-membered heterocyclyl), —(C0-C3 alkyl)(5-6-membered heteroaryl) and —(C0-C3 alkyl)phenyl, wherein each Rn is independently optionally substituted with halogen, C1-C3 alkyl, oxo, —CF3, —(C0-C3 alkyl)ORr or —(C0-C3 alkyl)NRrRs; or two Rn are taken together to form —O(CH2)1-3O—;
each Ro is independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclyl, —C(O)Rr, —C(O)ORr,
—C(O)NRrRs, —NRrC(O)Rs, —S(O)1-2Rr, —NRrS(O)1-2Rs and —S(O)1-2NRrRs, wherein said alkyl, cycloalkyl and heterocyclyl are independently optionally substituted by oxo, C1-C3 alkyl, ORr, NRrRs or halogen; and each RP is independently selected from the group consisting of hydrogen and C1-C3 alkyl, wherein said alkyl is independently optionally substituted by halogen or oxo; or Ro and RP are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl, optionally substituted by halogen, oxo, —CF3 or C1-C3 alkyl;
each Rr and Rs is independently selected from the group consisting of hydrogen and C1-C3 alkyl optionally substituted by halogen or oxo; or Rr and Rs are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl, optionally substituted by halogen, oxo, —CF3 or C1-C3 alkyl; and
X is a 9-10 membered bicyclic heteroaryl that comprises 2 or 3 atoms each independently selected from the group consisting of O, S, and N, wherein the 9-10 membered bicyclic heteroaryl is optionally substituted with Ru; provided X is not,
optionally substituted with Ru;
each Ru is independently selected from the group consisting of hydrogen, halo, C1-C6 alkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclyl, —ORv, —C(O)Rv, —C(O)ORv, —C(O)NRvRw, —NRvRw, —NRvC(O)Rw, —S(O)1-2R, —NRvS(O)1-2Rw and —S(O)1-2NRvRw, wherein said alkyl, cycloalkyl and heterocyclyl are independently optionally substituted by oxo, C1-C3 alkyl, —ORv, —NRvRw or halogen; and
each Rv and Rw is independently selected from the group consisting of hydrogen and C1-C3 alkyl optionally substituted by halogen or oxo; or Rv and Rw are taken together with the atom to which they are attached to form a 3-6-membered heterocyclyl, optionally substituted by halogen, oxo, —CF3 or C1-C3 alkyl;
provided the compound or pharmaceutically acceptable salt is not:
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R1 is —(C0-C3alkyl)C(O)Ra, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof wherein R1 is H, methyl,

### Claim 4 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 is H or methyl.

### Claim 5 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is phenyl that is optionally substituted by 1-5 Rn.

### Claim 6 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is phenyl that is optionally substituted by 1-2 Rn.

### Claim 7 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is selected from:

### Claim 8 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is:

### Claim 9 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X selected from the group consisting of:
and is optionally substituted with Ru.

### Claim 10 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X selected from the group consisting of:

### Claim 11 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X is not selected from the group consisting of:

### Claim 12 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X selected from the group consisting of:
and is optionally substituted with Ru.

### Claim 13 (depends on 1)

A compound of claim 1, selected from the group consisting of:
wherein:
Ru1 is H or methyl;
Ru2 is methyl or difluoromethyl; and
Ru3 is methyl, methoxy, halo, or NH2;
or a pharmaceutically acceptable salt thereof.

### Claim 14

A compound selected from the group consisting of:
wherein:
Ru1 is H or methyl; and
RU2 is methyl or difluoromethyl;
or a pharmaceutically acceptable salt thereof.

### Claim 15

A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 17 (depends on 1)

A method of preventing, treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the disease or condition is asthma.

### Claim 19 (depends on 17)

The method of claim 17, wherein the Janus kinase is JAK1.
